Lantheus(NASDAQ) LNTH

Lantheus Holdings, Inc. helps doctors see inside the body. It makes special fluids used for medical imaging scans. These tools help identify cancer and heart problems early.

Tools for Precise Diagnosis

• Oncology: PYLARIFY imaging agent for finding prostate cancer using a protein called prostate-specific membrane antigen (PSMA); generated $240.4 million in revenue for the three months ended June 30, 2026.
• Cardiology: DEFINITY microbubble agent used to improve the clarity of ultrasound heart scans; generated $88.3 million in revenue for the three months ended June 30, 2026.
• Neurology: Neuraceq positron emission tomography (PET) imaging tool used for Alzheimer's disease evaluation; produced $39.6 million in revenue for the three months ended June 30, 2026.
• Strategic Partnerships: Provides biomarkers and contract development and manufacturing organization (CDMO) services to other healthcare firms; generated $19.9 million in revenue for the three months ended June 30, 2026.

Growing Through Strategic Moves

• Entered a merger agreement with Curium US Holdings LLC on August 3, 2026, for $102.50 per share in cash.
• Completed the sale of the nuclear medicine business (SPECT) to SHINE on January 1, 2026, for approximately $131.2 million.
• Acquired Lantheus Biosciences in July 2025 to add new diagnostic tools for patients with Alzheimer's disease.
• Purchased Evergreen Theragnostics in April 2025 to improve manufacturing capabilities and drug discovery efforts.
• Received Food and Drug Administration (FDA) approval for PYLARIFY TruVu, a new imaging agent formulation, on March 6, 2026.

A Fast-Moving Supply Chain

Lantheus operates a global network of manufacturing sites to deliver imaging agents that have very short lifespans. Its reach extends across North America and Europe through direct sales and third-party distribution partners.

Recent Financial Results

• Revenue reached $388.2 million for the three months ended June 30, 2026, up 2.7% year over year.
• Net income was $75.0 million for the three months ended June 30, 2026, down 4.7% year over year.
• Market capitalization for the company reached $7.2 billion in the second quarter of 2026, up 28.5% year over year.
• The price-to-earnings ratio was 24.1 for the quarter ended June 30, 2026, up 35.5% year over year.

The Lantheus Evolution

Lantheus has shifted its focus toward high-growth radiopharmaceuticals through strategic acquisitions and new product approvals. Its move to divest older businesses and join with a larger partner marks a new phase in the company history.